• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword kerx

Total: 50 results found.

Keryx to Host Investor Conference Call Tomorrow, Monday, August 9, 2010 at 8:30am EDTNEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company ...
Investor Conference Call to be held Monday, August 9, 2010 at 8:30am EDTNEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the ...
... (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, ...
... section of the application is completed before the entire application can be reviewed. Investors should remember that when KERX landed Fast-Track designation for Perifosine back in April, it sent their ...
... on August 4, 2010. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Joseph Feczko, M.D. to the Company's Board of Directors. MWI Veterinary Supply, Inc. (NASDAQ: WIV) ...
NEW YORK, July 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Joseph Feczko, M.D. to the Company's Board of Directors.  ...
... in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), has been granted orphan-drug designation by the U.S. Food and Drug Administration for ...
... announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), has been granted orphan-drug designation by the U.S. Food and Drug Administration ("FDA") for perifosine, Aeterna Zentaris' ...
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration ...
... perifosine, in refractory advanced colorectal cancer. The trial is being sponsored by Keryx Biopharmaceuticals, Inc., (Keryx), (NASDAQ:KERX), Aeterna Zentaris' licensee for perifosine in North America. ...
... (FDA), is currently open and enrolling patients at multiple centers throughout the U.S. This Phase 3 trial is sponsored by Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), Aeterna Zentaris' licensee ...
... compound, perifosine, in refractory advanced colorectal cancer. The trial is being sponsored by Keryx Biopharmaceuticals, Inc., (Keryx), (NASDAQ: KERX), Aeterna Zentaris' licensee for perifosine in North ...
... used primarily in connection with perifosine, the Company's lead oncology compound that is being developed in collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) ...
... collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), following various positive developments announced with respect to perifosine during the first quarter of 2010. ...
... for several other tumor types. Perifosine is licensed to Keryx Biopharmaceuticals Inc. (Keryx) (Nasdaq: KERX), in the United States, ...
...  NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported ...
... types. Perifosine is licensed to Keryx Biopharmaceuticals Inc. (Keryx) (Nasdaq: KERX), in the United States, Canada and Mexico. ...
... Inc. (Nasdaq: KERX) today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at ...
NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following June ...
... $0.20 per share. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two presentations on clinical data from KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral ...
NEW YORK-- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two presentations on clinical data from KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer ...
... neuroblastoma, in pediatric patients. Perifosine is licensed to Keryx Biopharmaceuticals (Keryx) (Nasdaq:KERX - News), in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine ...
... including neuroblastoma, in pediatric patients. Perifosine is licensed to Keryx Biopharmaceuticals (Keryx) ( KERX), in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine ...
... KERX) today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor ...
... updating predictions or financial expectations contained in this release. VIVITROL® is a registered trademark and LinkeRxâ„¢ and Medifusionâ„¢ are trademarks of Alkermes, Inc.; RISPERDAL® CONSTA® ...
... by Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), Aeterna Zentaris' partner and licensee for perifosine in North America. - March 1, 2010: Disclosure that the Committee for Orphan Medicinal Products ...
... updating predictions or financial expectations contained in this release. VIVITROL® is a registered trademark and LinkeRxâ„¢ and Medifusionâ„¢ are trademarks of Alkermes, Inc.; RISPERDAL® CONSTA® ...
...  Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), today announced its results for the first quarter ended March 31, 2010.At March 31, 2010, the Company had cash, cash equivalents, interest receivable, and ...
Investor Conference Call to be held Tuesday, May 11, 2010 at 8:30am EDTNEW YORK, May 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the ...
Keryx to Host Investor Conference Call on Tuesday, May 11, 2010 at 8:30am EDTNEW YORK, May 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused ...
... OXIGON(TM) (OX1), which has potential for the treatment of Alzheimer's disease and other important indications. Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) pushed higher today after the company announced ...
Program conducted pursuant to Special Protocol Assessment Agreement with Food and Drug AdministrationNEW YORK, May 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today ...
... views on medication adherence and their perceptions about the role of their specialty pharmacy. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that preclinical data in neuroblastoma for ...
NEW YORK -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that preclinical data in neuroblastoma for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer ...
... the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the pivotal studies in each of the lead indications, which will be sponsored by Keryx Biopharmaceuticals Inc., (NASDAQ:KERX), ...
NEW YORK, April 15 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported updated long-term efficacy and safety data on Zerenex™ (ferric citrate), the Company's iron-based ...
... Assessment (SPA) for the pivotal studies in each of the lead indications, which will be sponsored by Keryx Biopharmaceuticals Inc., (Keryx), ( KERX), Æterna Zentaris's licensee for perifosine in North ...
... Inc. (Nasdaq: KERX) today announced that several posters on Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) ...
... The trial is sponsored and conducted by Keryx Biopharmaceuticals (Nasdaq:KERX), Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Æterna Zentaris has also out-licensed ...
... treatment of refractory advanced colorectal cancer.   The trial is sponsored and conducted by Keryx Biopharmaceuticals ("Keryx") ( KERX), Æterna Zentaris' partner and licensee for perifosine in the ...
  Below is a list of the companies that made news in the healthcare sector on Monday, April 05, 2010. Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) soared today after the company announced that ...
NEW YORK, April 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 ...
Keryx to Host Investor Conference Call on Thursday, March 25, 2010 at 8:30am EDTNEW YORK, March 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused ...
NEW YORK, March 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Thursday, March 25, 2010 at 8:30 a.m. EDT to discuss the fourth quarter andyear ...
... Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr. ...
... Inc. (KERX): Biotechnology & Healthcare Kid Brands, Inc. (KID): Retail & Consumer Products KIT Digital, Inc. (KITD): Advertising, Media & Internet KMG Chemicals, Inc.(KMGB): Industrials  ...
Presentation Scheduled for Thursday, March 11 at 11:05am EST NEW YORK, March 5 /PRNewswire-FirstCall/ -- Kerx Biopharmaceuticals, ...
...  Joe's Jeans Inc. (JOEZ): Retail & Consumer Products Kadant Inc. (KAI): Industrials Keryx Biopharmaceuticals Inc. (KERX): Biotechnology & Healthcare Kid Brands, Inc. (KID): Retail & Consumer ...
... Biopharmaceuticals, Inc. ( KERX), Æterna Zentaris' partner and licensee for perifosine in the North American market, already announced in September 2009 that it has received Orphan Drug Designation for ...
... & Industrials: China TrackJoe's Jeans Inc. (JOEZ): Retail & Consumer ProductsKadant Inc. (KAI): IndustrialsKeryx Biopharmaceuticals Inc. (KERX): Biotechnology & HealthcareKid Brands, Inc. ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved